Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 153339 in Healthy Subjects
NCT04883333Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of LEO 153339 (16 arms), sponsored by LEO Pharma. Primary endpoint: Number of treatment-emergent adverse events per subject at 10 days. Started May 2021; status: completed.
02
Drugs
LEO 153339
Beyond the preview
Go deeper on NCT04883333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883333.